What The Pandemic Can Teach Us About Running Clinical Trials
Lessons For Study Design, Analysis & EU Harmonization
Executive Summary
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.
You may also be interested in...
Coronavirus Notebook: EMA Focuses On EU Drug Supply Amid Fears Of Second Wave
In this latest update to coronavirus developments in the EU, the European Medicines Agency outlines plans to monitor demand for medicines in anticipation of a possible second wave of the COVID-19 pandemic later this year. It has also updated its adverse drug reaction literature monitoring service to cover potential coronavirus treatments, and backed the use of ACE-inhibitors and sartans during the pandemic.
EU Allows More Flexibility In Managing Trials During COVID-19
The EU has issued revised guidance to ensure that clinical trials can continue taking place during the COVID-19 pandemic.
Yet More Delay For EU Clinical Trial Regulation
Revisions and restructuring of the contract with the developers mean that Europe’s new clinical trials system will not go live next year as planned, although the European Medicines Agency says progress has been made with development of the system.